Development and Commercialisation of an Intelligent Wearable Platforms to Stabil...
Development and Commercialisation of an Intelligent Wearable Platforms to Stabilise Hand Tremors in Parkinson s Disease and Essential Tremor
GyroGlove is a wearable active device based on miniaturised gyroscopes, designed to suppress the hand tremor commonly
seen in people suffering from Parkinson’s Disease (PD) or Essential Tremor (ET). With the help of Innovate UK Pr...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Información proyecto GyroGlove
Duración del proyecto: 46 meses
Fecha Inicio: 2018-10-25
Fecha Fin: 2022-08-31
Líder del proyecto
GYROGEAR LIMITED
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
3M€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
GyroGlove is a wearable active device based on miniaturised gyroscopes, designed to suppress the hand tremor commonly
seen in people suffering from Parkinson’s Disease (PD) or Essential Tremor (ET). With the help of Innovate UK Proof of
Concept (PoC) grant we have taken the idea from very early lab simulators through to functional prototypes. These were
tested on PD and ET patients in lab conditions. We were able to demonstrate a 50% reduction in tremor in half of the tests
and as much as 95% in one case. GyroGlove has commenced pre-production development (as of Nov 2017). The team
has achieved TRL 6 as of this application and demonstrated proof-of-concept with group patient tests (30 users). The
GyroGlove form-factor comprises a lightweight/comfortable mount for an enclosed gyroscope which spins at approximately
20,000 RPM. By stabilising the hand directly, the GyroGlove is targeted at multi-function use (eating, drinking, writing, selfcare
etc.) to return independence and freedom to users. Given development and user testing success thus far, the phase 2
project will enable us to: finalise engineering design specification; build functional and pre-production prototypes; transfer to
manufacture; conduct clinical trials and gain regulatory approval; develop supply chain agreements and commercial
contracts ready for full commercialisation and multiple-market entry in Q4 2022 .